- Federal Reserve: Data driven rate path – HSBC
- The US and Iran offer conflicting statements as negotiations reach a stalemate, leaving the future of the Hormuz Agreement uncertain.
- According to the latest panel industry analysis by Trend Force, as production capacity continues to shrink and the industrial landscape shifts, it is estimated that by 2028, the combined supply share of Innolux and AUO in LCD monitor panels will fall below 10%, while the supply of LCD laptop panels will continue to decrease to nearly 20%. The supply ratio of LCD TV panels, as they still remain profitable, is expected to remain around 22%. The recent series of capacity reductions and asset optim
- NASDAQ TRADE HALT <LNTH.O> HALT NEWS PENDING AT 07:25 AM
- NASDAQ TRADE HALT CONTINUES <OCLTU.O> REASON NOT AVAILABLE AT 07:25 AM
- Algorand Eyes Recovery as Post-Quantum Roadmap Boosts Sentiment—Can ALGO Price Break Above $0.1?
- XRP Maintains Controlled Correction as Historical Pattern Suggests Major Weekly Rally Ahead
- Cardano Repeats Historic Bull Market Structure as Analyst Eyes Over 1,300% Upside to $2.9
- Truist Securities upgrades Corning to Buy with $175 price target, citing AI-driven optical demand
- Twist Bioscience FY26 Q3 adjusted EBITDA loss narrows to $(11.3) million; revenue rises 23% YoY to $118.4 million
- Twist Bioscience Sees 4Q Rev $123M-$124M >TWST
- Marriott schedules quarterly earnings call for investment community and media
- Bitcoin price prediction: Market conditions improve, but BTC needs THIS for a rally
- Twist Bioscience 3Q Research and Development Expenses $18M >TWST
- Twist Bioscience Raises FY26 View To Rev $456M-$457M >TWST
- Mapletree Industrial Trust issues 824,584 units at S$ 1.94 to pay manager base fee
- Precision BioSciences CFO Naresh Tanna files initial beneficial ownership statement
- M/I HOMES INC <MHO.N>: RAYMOND JAMES RAISES TARGET PRICE TO $175 FROM $155
- Twist Bioscience 3Q Loss/Shr 56c >TWST
- FIRST BUSINESS FINANCIAL SERVICES INC <FBIZ.O>: RAYMOND JAMES RAISES TARGET PRICE TO $78 FROM $64
- EOG RESOURCES INC <EOG.N>: RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $176
- IQM Quantum Computers registers 183,619 ESOP 1 shares, raising EUR 74,393.8
- Twist Bioscience 3Q Rev $118.4M >TWST
- Twist Bioscience posts fiscal Q3 2026 earnings report and investor presentation online
- Twist Bioscience posts fiscal Q3 2026 investor presentation
- Nexans buys back 6,449 shares on Paris exchange at average EUR 128.15-134.16 under buyback mandate
- Fleury Michon buys back 1,289 shares at average EUR 21.93 under share repurchase program
- PayPoint reports 59,547,621 total voting rights as of July 31, 2026
- CHURCH & DWIGHT CO INC <CHD.N>: RAYMOND JAMES RAISES TARGET PRICE TO $112 FROM $110
- BROWN & BROWN INC <BRO.N>: RAYMOND JAMES RAISES TARGET PRICE TO $80 FROM $70
- Compugen posts investor presentation on immuno-oncology antibody pipeline, partnerships and cash runway
- Autolus raises FY 2026 sales forecast to $140 million-$150 million
- BRIGHTSPRING HEALTH SERVICES INC <BTSG.O>: RAYMOND JAMES CUTS TARGET PRICE TO $75 FROM $80
- Glaukos publishes investor presentation highlighting interventional glaucoma, keratoconus pipeline programs
- TETRA TECH INC (DELAWARE) <TTEK.O>: RBC RAISES TARGET PRICE TO $46 FROM $43
- ALERUS FINANCIAL CORP : RAYMOND JAMES RAISES TARGET PRICE TO $37 FROM $34
- Compugen publishes corporate presentation on AI-driven immuno-oncology antibody pipeline
- Anima H1 FY26 net profit rises 3% to €158.8 million; revenue climbs 16% to €286.8 million
- Luckin Coffee Q2 net revenue reached 15.89 billion RMB, up 29% year-over-year, exceeding the estimated 15.43 billion RMB. Q2 net profit was 1.49 billion RMB, a year-over-year increase of 19%. Adjusted net earnings per ADS for Q2 were 5.44 RMB.
- Bernstein raises Apple (AAPL.US) target price from $350 to $370.
- Public Policy Holding: Such Future Payments to Be Satisfied by Mix of Cash and Equity, and Maximum Amount Payable Is $54.6M >PPHC
- Public Policy Holding: Future Earnout Payments Contingent on TAP Delivering Profit Growth Between 2026 and 2030 >PPHC
- Public Policy Holding: Future Earnout Payments Could Be Made With the Final Payment Taking Place After the End of 2030 >PPHC
- Sif names Koen Bogers CEO, replacing Fred van Beers
- PROTO LABS INC : NEEDHAM RAISES TO BUY FROM HOLD
- Vodafone completes VodafoneZiggo stake sale to Liberty Global for EUR 1 billion cash, 10% Ziggo Group stake
- 10-Yr Benchmark Govt Yields - Germany vs Other Nations
- Public Policy Holding: Initial Consideration Paid in Part Via Issuance of Shrs, Totaling $2.04M; Balance of $18.36M Paid in Cash, Funded From Co's Balance Sheet >PPHC
- 2-Yr Benchmark Govt Yields - Germany vs Other Nations
- 10-Yr Benchmark Govt Yields - U.S. vs Other Nations
- 2-Yr Benchmark Govt Yields - U.S. vs Other Nations
- Star Bulk COO Nikolaos Reskos sells 5,000 common shares worth $144,950
- Public Policy Holding: Initial Consideration of $20.4M Was Satisfied on Completion, Which Occurred Aug 1 >PPHC
- Public Policy Holding: For Yr Ended Dec 31, 2025, TAP Reported Net Rev of $9.5M >PPHC
- ADIAL PHARMACEUTICALS INC : ALLIANCE GLOBAL PARTNERS INITIATES COVERAGE WITH BUY RATING; PRICE TARGET $11
- Public Policy Holding Says Acquisition Is Immediately Earnings Accretive >PPHC
- PBF ENERGY INC : JP MORGAN RAISES TARGET PRICE TO $83 FROM $57
- DOORDASH <DASH.O>: BENCHMARK CUTS TARGET PRICE TO $270 FROM $285
- TG Therapeutics Raises 2026 Target BRIUMVI U.S. Net Product Revenue to About $890-$905 Million >TGTX
- Avista 2Q Adj EPS 29c >AVA
- TG Therapeutics Raises 2026 View To Rev $950M >TGTX
- BRIEF-Avista Q2 EPS USD 0.43
- CORNING <GLW.N>: TRUIST SECURITIES RAISES TO BUY FROM HOLD; CUTS TARGET PRICE TO $175 FROM $205
- GALAXY DIGITAL INC <GLXY.O>: ROSENBLATT SECURITIES CUTS TARGET PRICE TO $35 FROM $39
- Regenxbio schedules conference call to discuss second-quarter results and operational update
- Krystal Biotech Q2 net income rises 43% to $54.8 million; revenue climbs 24% to $119.2 million
- DO & CO extends CEO Attila Dogudan’s term to July 2029
- Ninety One repurchases shares for GBP 14.98 million under buyback program
- BCB Bancorp Q2 FY26 turns to net loss of $14.8 million; loss per share widens to $0.85
- Marriott 2Q Adjusted Ebitda $1.59B >MAR
- Marriott Sees 2026 Worldwide RevPAR Up 3%-3.5% >MAR
- Air Industries: Parties to Extend Outside Date by 60 Days, Nov 30 >AIRI
- TG Therapeutics 2Q Rev $240.3M >TGTX
- Marriott Sees 2026 Investment Spending $1.25B-$1.35B >MAR
- Marriott Sees 2026 Adjusted Ebitda $5.965B-$6.025B >MAR
- Krystal Biotech 2Q Rev $119.2M >KRYS
- Z Squared agrees to buy Paradox Data, expands deal to 100% acquisition
- Air Industries extends Tenax Aerospace merger outside date to Nov. 30, 2026
- Ocular Therapeutix Q2 FY26 net loss widens to $78.76 million; revenue rises 0.12% to $13.48 million
- CSW INDUSTRIALS INC <CSW.N>: TRUIST SECURITIES RAISES TARGET PRICE TO $332 FROM $313
- Seaport Therapeutics 2Q Research and Development Expenses Were $24.6M >SPTX
- Ellington Credit Company updates financial calendar with earnings release and conference call schedule
- ALNYLAM PHARMACEUTICALS INC : BERNSTEIN CUTS TARGET PRICE TO $376 FROM $429
- Sportradar turns to Q2 FY26 net loss of €4 million; revenue rises 19% to €378 million
- Chevron expands North America base oils distribution via HF Sinclair, Renkert Oil deals
- Klappir Green Solutions calls extraordinary shareholders meeting
- Marriott Sees 3Q Adjusted Ebitda $1.44B-$1.47B >MAR
- Seaport Therapeutics 2Q Loss/Shr $1.78 >SPTX
- Marriott 2Q Comparable System-Wide U.S. & Canada Constant Dollar RevPAR Up 5.0% >MAR
- Dow Jones Top Financial Services Headlines at 7 AM ET: Fed's Barkin Says It's a 'Close Call' Whether Rates Are High Enough | Three ...
- Marriott 2Q Rev $7.07B >MAR
- Marriott 2Q Comparable System-Wide Worldwide Constant Dollar RevPAR Up 3.4% >MAR
- Marriott 2Q Net $766M >MAR
- Ocular Therapeutix 2Q Loss $78.8M >OCUL
- Marriott 2Q EPS $2.90 >MAR
- Marriott Sees 3Q Adj EPS $2.74-Adj EPS $2.82 >MAR
- Marriott 2Q Comparable System-Wide Intl Constant Dollar RevPAR Down 0.5% >MAR
- Marriott Sees FY Adj EPS $11.64-Adj EPS $11.81 >MAR
- BCB Bancorp 2Q Loss/Shr 85c >BCBP
- Ocular Therapeutix 2Q Loss/Shr 35c >OCUL
